Caprock Group LLC Makes New Investment in Sanofi $SNY

Caprock Group LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 27,229 shares of the company’s stock, valued at approximately $1,347,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Financial Consulate Inc. bought a new stake in Sanofi in the third quarter worth $26,000. First Horizon Corp bought a new stake in shares of Sanofi in the 3rd quarter worth about $33,000. Salomon & Ludwin LLC boosted its stake in shares of Sanofi by 1,046.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock worth $39,000 after purchasing an additional 701 shares during the period. Nisa Investment Advisors LLC raised its position in Sanofi by 233.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after purchasing an additional 700 shares during the period. Finally, Traub Capital Management LLC bought a new stake in Sanofi in the second quarter worth about $51,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SNY. TD Cowen restated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Barclays lowered shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Citigroup started coverage on shares of Sanofi in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. Finally, Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Five research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $62.67.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Sanofi Price Performance

NASDAQ SNY opened at $46.01 on Friday. The company has a market cap of $112.22 billion, a PE ratio of 12.78, a P/E/G ratio of 1.20 and a beta of 0.45. The firm’s 50 day moving average price is $47.73 and its 200-day moving average price is $48.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.29 and a current ratio of 1.09. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.